

DNDi HAT symposium at ASTMH 2008

Bayside BC Sheraton New Orleans USA

For more information, please visit DND/s booth (#209) at ASTMH 08 or www.dndi.org

Addressing the R&D challenges

in making new drugs available for human African trypanosomiasis: potential in the pipeline and recent clinical results

Monday, December 8, 2008 10:15 am - 12:00 pm

CHAIRS:

Leon Kazumba HAT Platform, Kinshasa, DRC Pere Simarro WHO, Geneva, Switzerland







Addressing the R&D challenges

in making new drugs available for human African trypanosomiasis (HAT): potential in the pipeline and recent clinical results

HAT symposium, ASTMH 2008 Sheraton New Orleans, USA Monday, December 8, 2008



- HAT Platform Success to date, and challenges/opportunities ahead in overcoming difficulties in clinical research of HAT drugs & in developing regional research platform
 Fred Kansiime, HAT Platform, Coordination Office for Control of Trypanosomiasis in Uganda, Kampala, Uganda
- Phase III results of multi-center study evaluating nifurtimox-eflorthine combination for treatment (NECT) of Stage 2 HAT
 Gerardo Priotto, Epicentre, Paris, France
- Research results evaluating the diamidine class for the treatment of HAT Carol Olson, Immtech Pharmaceuticals, Vernon Hills, IL, United States
- Fexinidazole: a rediscovered nitroimidazole drug candidate moving into clinical development for HAT

Els Torreele, Drugs for Neglected Diseases initiative, Geneva, Switzerland

Interventions by Christian Burri, Swiss Tropical Institute, Basel, Switzerland, and Constantin Miaka Mia Bilenge, HAT National Control Program, Kinshasa, Democratic Republic of the Congo (DRC), followed by a Q&A session

DNDi's HAT symposium will be followed by film broadcast on HAT: "Sleeping sickness: the deadliest disease", BBC series "Survival", produced by Rockhopper TV.

At 12:15 pm, Room: Bayside BC